Pim kinases phosphorylate Chk1 and regulate its functions in acute myeloid leukemia

Leukemia

Volumn 28, Issue 2, 2014, Pages 293-301

  Yuan, L L ^a   Green, A S ^b   Bertoli, S ^a   Grimal, F ^a   Mansat De Mas, V ^a   Dozier, C ^a   Tamburini, J ^b   Recher C ^a   Didier, C ^a   Manenti, S ^a  

^a CHU PURPAN   (France)

^b INSTITUT COCHIN   (France)

Author keywords

acute myeloid leukemia; checkpoint; CHK1; FLT3 ITD; Pim

Indexed keywords

CD135 ANTIGEN; CHECKPOINT KINASE 1; DNA; ETOPOSIDE; HISTONE H3; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE PIM 1; PROTEIN KINASE PIM 2; PROTEIN TYROSINE PHOSPHATASE; RNA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER CELL; CATALYSIS; CELL CYCLE; CONTROLLED STUDY; CYTOPLASM; DNA DAMAGE; ENZYME INACTIVATION; G2 PHASE CELL CYCLE CHECKPOINT; GENE MUTATION; GENETIC STABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; M PHASE CELL CYCLE CHECKPOINT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE;

CELL LINE, TUMOR; FMS-LIKE TYROSINE KINASE 3; GENE DUPLICATION; HUMANS; INTRACELLULAR SPACE; LEUKEMIA, MYELOID, ACUTE; PHOSPHORYLATION; PROTEIN KINASES; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-PIM-1; SERINE; SIGNAL TRANSDUCTION;

EID: 84893732464     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.168     Document Type: Article

References (34)

1. Dai Y, Grant S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res 2010; 16: 376-383.
2. Petermann E, Maya-Mendoza A, Zachos G, Gillespie DA, Jackson DA, Caldecott KW. Chk1 requirement for high global rates of replication fork progression during normal vertebrate S phase. Mol Cell Biol 2006; 26: 3319-3326.
3. Petermann E, Woodcock M, Helleday T. Chk1 promotes replication fork progression by controlling replication initiation. Proc Natl Acad Sci USA 2010; 107: 16090-16095.
4. Syljuasen RG, Sørensen CS, Hansen LT, Fugger K, Lundin C, Johansson F et al. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol Cell Biol 2005; 25: 3553-3562.
5. Krämer A, Mailand N, Lukas C, Syljuåsen RG, Wilkinson CJ, Nigg EA et al. Centrosome-associated Chk1 prevents premature activation of cyclin-B-Cdk1 kinase. Nat Cell Biol 2004; 6: 884-891.
6. Zachos G, Black EJ, Walker M, Scott MT, Vagnarelli P, Earnshaw WC et al. Chk1 is required for spindle checkpoint function. Dev Cell 2007; 12: 247-260.
7. Kasahara K, Goto H, Enomoto M, Tomono Y, Kiyono T, Inagaki M. 14-3-3gamma mediates Cdc25A proteolysis to block premature mitotic entry after DNA damage. EMBO J 2010; 29: 2802-2812.
8. Xu N, Libertini S, Black EJ, Lao Y, Hegarat N, Walker M, Gillespie DA. Cdk-mediated phosphorylation of Chk1 is required for efficient activation and full checkpoint proficiency in response to DNA damage. Oncogene 2012; 31: 1086-1094.
9. Enomoto M, Goto H, Tomono Y, Kasahara K, Tsujimura K, Kiyono T et al. Novel positive feedback loop between Cdk1 and Chk1 in the nucleus during G2/M transition. J Biol Chem 2009; 284: 34223-34230.
10. King FW, Skeen J, Hay N, Shtivelman E. Inhibition of Chk1 by activated PKB/Akt. Cell Cycle 2004; 3: 634-637.
11. Puc J, Keniry M, Li HS, Pandita TK, Choudhury AD, Memeo L et al. Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell 2005; 7: 193-204.
12. Pabla N, Bhatt K, Dong Z. Checkpoint kinase 1 (Chk1)-short is a splice variant and endogenous inhibitor of Chk1 that regulates cell cycle and DNA damage checkpoints. Proc Natl Acad Sci USA 2012; 109: 197-202.
13. Chung KY, Morrone G, Schuringa JJ, Wong B, Dorn DC, Moore MA. Enforced expression of an Flt3 internal tandem duplication in human CD34\+ cells confers properties of self-renewal and enhanced erythropoiesis. Blood 2005; 105: 77-84.
14. Hayakawa F, Towatari M, Kiyoi H, Tanimoto M, Kitamura T, Saito H et al. Tandemduplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 2000; 19: 624-631.
15. Kiyoi H, Naoe T. FLT3 in human hematologic malignancies. Leuk Lymphoma 2002; 43: 1541-1547.
16. Mizuki M, Schwable J, Steur C, Choudhary C, Agrawal S, Sargin B et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood 2003; 101: 3164-3173.
17. Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 2003; 3: 650-665.
18. Kim KT, Baird K, Ahn JY, Meltzer P, Lilly M, Levis M et al. Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood 2005; 105: 1759-1767.
19. Grundler R, Brault L, Gasser C, Bullock AN, Dechow T, Woetzel S et al. Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration. J Exp Med 2009; 206: 1957-1970.
20. Nawijn MC, Alendar A, Berns A. For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer 2011; 11: 23-34.
21. Tamburini J, Green AS, Bardet V, Chapuis N, Park S, Willems L et al. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood 2009; 114: 1618-1627.
22. Hospital MA, Green AS, Lacombe C, Mayeux P, Bouscary D, Tamburini J. The FLT3 and Pim kinases inhibitor SGI-1776 preferentially target FLT3-ITD AML cells. Blood 2012; 119: 1791-1792.
23. Brault L, Gasser C, Bracher F, Huber K, Knapp S, Schwaller J. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica 2010; 95: 1004-1015.
24. Amico D, Barbui AM, Erba E, Rambaldi A, Introna M, Golay J. Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3. Blood 2003; 101: 4589-4597.
25. Sampath D, Cortes J, Estrov Z, Du M, Shi Z, Andreeff M et al. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood 2006; 107: 2517-2524.
26. Didier C, Cavelier C, Quaranta M, Galcera MO, Demur C, Laurent G et al. G2/M checkpoint stringency is a key parameter in the sensitivity of AML cells to genotoxic stress. Oncogene 2008; 27: 3811-3820.
27. Cavelier C, Didier C, Prade N, Mansat-De Mas V, Manenti S, Recher C et al. Constitutive activation of the DNA damage signaling pathway in acute myeloid leukemia with complex karyotype: potential importance for checkpoint targeting therapy. Cancer Res 2009; 69: 8652-8661.
28. Didier C, Demur C, Grimal F, Jullien D, Manenti S, Ducommun B. Evaluation of checkpoint kinase targeting therapy in acute myeloid leukemia with complex karyotype. Cancer Biol Ther 2012; 13: 307-313.
29. Furet P, Bold G, Meyer T, Roesel J, Guagnano V. Aromatic interactions with phenylalanine 691 and cysteine 828: a concept for FMS-like tyrosine kinase-3 inhibition. Application to the discovery of a new class of potential antileukemia agents. J Med Chem 2006; 49: 4451-4454.
30. Shimada M, Niida H, Zineldeen DH, Tagami H, Tanaka M, Saito H, Nakanishi M. Chk1 is a histone H3 threonine 11 kinase that regulates DNA damage-induced transcriptional repression. Cell 2008; 132: 221-232.
31. Sexauer A, Perl A, Yang X, Borowitz M, Gocke C, Rajkhowa T et al. Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. Blood 2012; 120: 4205-4214.
32. Xu N, Hegarat N, Black EJ, Scott MT, Hochegger H, Gillespie DA. Akt/PKB suppresses DNA damage processing and checkpoint activation in late G2. J Cell Biol 2010; 190: 297-305.
33. Tonic I, Yu WN, Park Y, Chen CC, Hay N. Akt activation emulates Chk1 inhibition and Bcl2 overexpression and abrogates G2 cell cycle checkpoint by inhibiting BRCA1 foci. J Biol Chem 2010; 285: 23790-23798.
34. Li P, Goto H, Kasahara K, Matsuyama M, Wang Z, Yatabe Y et al. P90 RSK arranges Chk1 in the nucleus for monitoring of genomic integrity during cell proliferation. Mol Biol Cell 2012; 23: 1582-1592.